- Home
- PWP vs AUPH Comparison
PWP vs AUPH Comparison
Compare PWP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWP
- AUPH
- Stock Information
- Founded
- PWP 2006
- AUPH 1993
- Country
- PWP United States
- AUPH Canada
- Employees
- PWP N/A
- AUPH N/A
- Industry
- PWP Finance: Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PWP Finance
- AUPH Health Care
- Exchange
- PWP Nasdaq
- AUPH Nasdaq
- Market Cap
- PWP 1.4B
- AUPH 1.1B
- IPO Year
- PWP N/A
- AUPH 1999
- Fundamental
- Price
- PWP $23.49
- AUPH $7.93
- Analyst Decision
- PWP Buy
- AUPH Strong Buy
- Analyst Count
- PWP 2
- AUPH 3
- Target Price
- PWP $27.50
- AUPH $10.33
- AVG Volume (30 Days)
- PWP 722.5K
- AUPH 1.0M
- Earning Date
- PWP 02-07-2025
- AUPH 02-27-2025
- Dividend Yield
- PWP 1.19%
- AUPH N/A
- EPS Growth
- PWP N/A
- AUPH N/A
- EPS
- PWP N/A
- AUPH N/A
- Revenue
- PWP $878,039,000.00
- AUPH $220,361,000.00
- Revenue This Year
- PWP $17.99
- AUPH $36.97
- Revenue Next Year
- PWP $12.07
- AUPH $16.43
- P/E Ratio
- PWP N/A
- AUPH N/A
- Revenue Growth
- PWP 35.42
- AUPH 38.72
- 52 Week Low
- PWP $11.68
- AUPH $4.71
- 52 Week High
- PWP $27.03
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- PWP 43.21
- AUPH 47.47
- Support Level
- PWP $22.66
- AUPH $7.50
- Resistance Level
- PWP $24.34
- AUPH $8.12
- Average True Range (ATR)
- PWP 0.99
- AUPH 0.27
- MACD
- PWP -0.17
- AUPH 0.02
- Stochastic Oscillator
- PWP 19.38
- AUPH 53.49
About PWP Perella Weinberg Partners
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.